00 / pharma& news

07/04/2021

Continuing to build up our organisation, following the acquisition of Pegasys, pharma& is pleased to welcome Detlef Jakschies, PhD as Medical & Scientific Director. Detlef will be responsible for leading and implementing pharma&’s medical and scientific strategies, developing customized solutions to best serve the patients’ needs, with a focus on our worldwide business for Pegasys (Peginterferon alfa 2a).

 

Detlef joins us with a strong background in the field of Interferons, ranging from research at the Medical School of Hannover to various commercial roles in the pharmaceutical industry over the last 20 years, focussing on scientific leadership in the field of haematology and oncology. Respected and valued for his deep scientific understanding and clinical know-how, he is regarded as a valuable partner for his customers and peers alike and has established a strong network within the scientific community.

18/02/2021

We are proud to announce that we recently signed an agreement

with F. Hoffmann-La Roche Ltd to acquire the worldwide rights of

Pegasys (Peginterferon alfa 2a) excl. China and Japan,

securing long-term access and supply for patients benefiting

from this well established therapy option.

For any inquiries please contact us at

Pegasys@pharmaand.com.

zr pharma& GmbH

Rauhensteingasse 10/14

1010 Vienna

Austria

  • LinkedIn - White Circle

LinkedIn

pharma& Schweiz GmbH

Poststrasse 30

6300 Zug

Switzerland

© 2021 by pharma&